Subcutaneous amivantamab and lazertinib as first-line treatment in patients with <i>EGFR</i>-mutated, advanced non-small cell lung cancer (NSCLC): Results from the phase 2 PALOMA-2 study.

Lim, Sun Min and Tan, Jiunn-Liang and Dias, Josiane Mourao and Voon, Pei Jye and How, Soon Hin and Zhou, Xiangdong and Xiong, Hailin and Massuti, Bartomeu and Medley, Louise C. and Nagasaka, Misako and Vicente, David and Girard, Nicolas and Rittmeyer, Achim and Botesteanu, Dana-Adriana and Alhadab, Ali and Mahoney, Janine M. and Zhang, Jie and Bauml, Joshua Michael and Baig, Mahadi and Scott, Susan Combs (2024) Subcutaneous amivantamab and lazertinib as first-line treatment in patients with <i>EGFR</i>-mutated, advanced non-small cell lung cancer (NSCLC): Results from the phase 2 PALOMA-2 study. Journal of Clinical Oncology, 42 (17_SUP). LBA8612. ISSN 0732-183X, DOI https://doi.org/10.1200/JCO.2024.42.17_suppl.LBA8612.

Full text not available from this repository.
Official URL: https://doi.org/10.1200/JCO.2024.42.17_suppl.LBA86...

Abstract

[no abstract]

Item Type: Article
Funders: Janssen Research Development
Uncontrolled Keywords: 283-197-481; 261-492-3532-2373; 613-3267-3650-3634-10059; 613-135-4642-282-153-924; 283-197-481; 613-225-2575-3984; 613-225-325; 613-225-2782; 6; 6; 3; 3; 3; 3; 3; 2; 4310; 3340; 194; 4310; 3340; 3; 3; 1; 1; 1
Subjects: R Medicine > R Medicine (General)
R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Divisions: Universiti Malaya Medical Centre (UMMC)
Depositing User: Ms. Juhaida Abd Rahim
Date Deposited: 16 Jan 2025 01:18
Last Modified: 16 Jan 2025 01:18
URI: http://eprints.um.edu.my/id/eprint/46894

Actions (login required)

View Item View Item